Autolus Therapeutics plc (6A3A) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.335x

Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has a cash flow conversion efficiency ratio of -0.335x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-25.07 Million ≈ $-29.31 Million USD) by net assets (€74.84 Million ≈ $87.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Autolus Therapeutics plc worth for the company's overall valuation and market capitalisation.

Autolus Therapeutics plc - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Autolus Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Autolus Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Autolus Therapeutics plc ranked by their cash flow conversion efficiency. See 6A3A debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Helen of Troy Limited F:HT2	0.139x
The York Water Company NASDAQ:YORW	0.022x
First Trust High Yield Opportunities 2027 Term Fund NYSE:FTHY	N/A
Beijing Huaru Technology Co. Ltd. SHE:301302	-0.072x
Anhui Transport Consulting & SHG:603357	0.009x
Jereissati Participações S.A. SA:IGTI3	0.010x
Vastned Retail Belgium BR:VASTB	0.012x
Radium Development Berhad KLSE:5313	0.010x

Annual Cash Flow Conversion Efficiency for Autolus Therapeutics plc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2025. View 6A3A live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€178.13 Million ≈ $208.25 Million	€-283.57 Million ≈ $-331.52 Million	-1.592x	-229.79%
2024-12-31	€427.32 Million ≈ $499.59 Million	€-206.27 Million ≈ $-241.15 Million	-0.483x	+63.04%
2023-12-31	€111.47 Million ≈ $130.32 Million	€-145.59 Million ≈ $-170.21 Million	-1.306x	-247.32%
2022-12-31	€298.67 Million ≈ $349.18 Million	€-112.31 Million ≈ $-131.30 Million	-0.376x	+0.04%
2021-12-31	€313.32 Million ≈ $366.30 Million	€-117.86 Million ≈ $-137.79 Million	-0.376x	+32.91%
2020-12-31	€210.03 Million ≈ $245.55 Million	€-117.76 Million ≈ $-137.67 Million	-0.561x	-40.79%
2019-12-31	€254.84 Million ≈ $297.93 Million	€-101.48 Million ≈ $-118.65 Million	-0.398x	-139.23%
2018-12-31	€255.47 Million ≈ $298.67 Million	€-42.52 Million ≈ $-49.72 Million	-0.166x	-45.09%
2017-12-31	€142.60 Million ≈ $166.72 Million	€-16.36 Million ≈ $-19.13 Million	-0.115x	--

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$522.77 Million

€447.15 Million EUR

Market Cap Rank

#12583 Global

#1343 in Germany

Share Price

€1.68

Change (1 day)

+3.07%

52-Week Range

€1.06 - €2.16

All Time High

€40.10